['axial spondyloarthritis']
['ixekizumab', 'placebo']

        Inclusion Criteria:

          -  Are ambulatory.

          -  Diagnosis of nonradiographic axial spondyloarthritis (nr-axSpA) and fulfilling the
             2009 Assessment of Spondyloarthritis International Society (ASAS) classification
             criteria.

          -  Have a history of back pain ≥3 months with age at onset <45 years.

          -  Have active nr-axSpA defined as BASDAI ≥4 and total back pain ≥4 on a numeric rating
             scale (NRS) at screening and baseline.

          -  Have objective signs of inflammation by presence of sacroiliitis on MRI and/or
             presence of elevated C-reactive protein (CRP).

          -  In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory
             drugs (NSAIDS) for duration of 4 weeks or cannot tolerate NSAIDS.

          -  If taking NSAIDS be on stable dose for at least 2 weeks prior to randomization.

          -  Have a history of prior therapy for axSpA for at least 12 weeks prior to screening.

        Exclusion Criteria:

          -  Have radiographic sacroiliitis fulfilling the 1984 modified New York criteria.

          -  Have received any prior, or are currently receiving treatment with biologics, tumor
             necrosis factor inhibitors or other immunomodulatory agents.

          -  Have received a live vaccine within 12 weeks or have had a vaccination with Bacillus
             Calmette-Guerin (BCG) within the past year.

          -  Have an ongoing or serious infection within the last 12 weeks or evidence of active
             tuberculosis.

          -  Have a compromised immune system.

          -  Have any other serious and/or uncontrolled diseases.

          -  Have either a current diagnosis or a recent history of malignant disease.

          -  Have had major surgery within 8 weeks of baseline, or will require surgery during the
             study.

          -  Are pregnant or breastfeeding.

          -  Have evidence of active anterior uveitis (an acute episode) within the last 42 days
             prior to baseline randomization.
      